Clinical Trial

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy

Study acronym: AERN
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of the trial is to improve efficacy of nivolumab in patients with relapsed or refractory HL who recently progressed on anti-PD1 therapy. Nivolumab is highly effective and well tolerated in rrHL, nevertheless CR-rates are low and a considerable proportion of patients suffers from progressive disease. Localized RT induces an immunogenic effect which might work synergistically and facilitate augmented systemic (i.e. abscopal) responses in combination with nivolumab.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2018-03-21; most recent amendment 2025-03-31.
Status change: Recruiting → Active, Not Recruiting 2024-07-25
Status change: Not Yet Recruiting → Recruiting 2019-07-19
Trial Details
NCT Number NCT03480334
Lead Sponsor University of Cologne
Conditions Classical Hodgkin Lymphoma
Enrollment 26 participants
Start Date 2019-12-05
Primary Completion 2024-05-04 (estimated)
Study Completion 2025-05-04 (estimated)
Updated on ClinicalTrials.gov 2025-04-03